Cabozantinib and dostarlimab for recurrent gynecologic carcinosarcoma
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests the combination of cabozantinib and dostarlimab to treat recurrent (coming back) gynecologic carcinosarcoma, after standard chemotherapy has already been tried. It aims to shrink tumors and improve outcomes by targeting cancer pathways.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have biopsy-proven carcinosarcoma (a specific cancer type), and it can start in any gynecologic area
- Your cancer has come back after at least one prior chemotherapy treatment
- Your scans show at least one measurable spot the study team can track
- You’ve recovered from prior treatment side effects to mild levels (generally no worse than Grade 1)
- You are able to do daily activities fairly well (ECOG 0 to 2) and are at least 18 years old
- Your blood counts and organ tests (kidney, liver, etc.) meet required lab levels
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a drug called dostarlimab (an immunotherapy that boosts your immune system to fight cancer) before and after surgery can help treat advanced endometrial cancer. It is for people with stage 3 or 4 endometrial cancer who haven't had treatment yet and may be eligible if their tumor has a specific marker called mismatch repair deficiency.
This Phase 1 trial studies how safe and tolerable it is to add dostarlimab (an immunotherapy) to standard chemo and radiation, followed by more chemotherapy, for stage IIIC endometrial cancer that has spread to lymph nodes. It aims to see whether this combination can be given safely soon after surgery.
This Phase 2 study tests whether adding dostarlimab (an immunotherapy medicine) to radiation after surgery can lower cancer returning and improve outcomes. It’s for people with certain endometrial cancers found to have specific genetic/molecular changes and who have stage III/IVA disease after surgery.
This trial tests a new drug called dostarlimab, given with standard chemotherapy, for people with advanced or recurrent endometrial cancer. It aims to see if this combination can help shrink tumors or slow their growth.
This trial tests a drug called dostarlimab alone or with bevacizumab compared to standard chemotherapy for women whose clear cell cancer of the ovary, uterus, cervix, vagina, or vulva has come back within a year of platinum chemotherapy. The goal is to see if these newer treatments can help control the cancer better.
This trial tests a drug called dostarlimab (an immunotherapy that helps your immune system fight cancer) in people with advanced or recurrent endometrial cancer. The goal is to see if the drug is safe and effective for this type of cancer.
Hear when a new Gynecologic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.